IL295542A - Compositions and methods for inducible alternative splicing regulation of gene expression - Google Patents

Compositions and methods for inducible alternative splicing regulation of gene expression

Info

Publication number
IL295542A
IL295542A IL295542A IL29554222A IL295542A IL 295542 A IL295542 A IL 295542A IL 295542 A IL295542 A IL 295542A IL 29554222 A IL29554222 A IL 29554222A IL 295542 A IL295542 A IL 295542A
Authority
IL
Israel
Prior art keywords
nucleic acid
acid molecule
exon
seq
pyridazin
Prior art date
Application number
IL295542A
Other languages
English (en)
Hebrew (he)
Inventor
T Ranum Paul
Mas Monteys Alejandro
A Hundley Amiel
L Davidson Beverly
Original Assignee
Childrens Hospital Philadelphia
T Ranum Paul
Mas Monteys Alejandro
A Hundley Amiel
L Davidson Beverly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia, T Ranum Paul, Mas Monteys Alejandro, A Hundley Amiel, L Davidson Beverly filed Critical Childrens Hospital Philadelphia
Publication of IL295542A publication Critical patent/IL295542A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
IL295542A 2020-02-12 2021-02-12 Compositions and methods for inducible alternative splicing regulation of gene expression IL295542A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975400P 2020-02-12 2020-02-12
PCT/US2021/017950 WO2021163556A1 (en) 2020-02-12 2021-02-12 Compositions and methods for inducible alternative splicing regulation of gene expression

Publications (1)

Publication Number Publication Date
IL295542A true IL295542A (en) 2022-10-01

Family

ID=77292961

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295542A IL295542A (en) 2020-02-12 2021-02-12 Compositions and methods for inducible alternative splicing regulation of gene expression

Country Status (9)

Country Link
US (1) US20230340498A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103717A4 (cg-RX-API-DMAC7.html)
JP (1) JP7728772B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220146501A (cg-RX-API-DMAC7.html)
CN (1) CN115605596A (cg-RX-API-DMAC7.html)
AU (1) AU2021218807A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167836A1 (cg-RX-API-DMAC7.html)
IL (1) IL295542A (cg-RX-API-DMAC7.html)
WO (1) WO2021163556A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355509A1 (en) * 2018-08-07 2021-11-18 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
CN115023242B (zh) 2019-11-22 2025-03-14 费城儿童医院 腺相关病毒载体变体
WO2023054573A1 (ja) * 2021-09-30 2023-04-06 国立大学法人大阪大学 相同染色体の一方に特異的なdna欠失を有する細胞を製造する方法
US20250346893A1 (en) * 2021-10-22 2025-11-13 Fred Hutchinson Cancer Center Synthetic introns for targeted gene expression
CA3254228A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR REGULATING INDUCIBLE ALTERNATIVE SPLICING OF GENE EXPRESSION
WO2024060205A1 (zh) * 2022-09-23 2024-03-28 北京基驭医疗科技有限公司 包含基于小分子药物的可变剪接调节元件的核酸分子
WO2024118610A2 (en) * 2022-11-28 2024-06-06 Siren Biotechnology, Inc. Gene therapy vectors for treatment of cancer
WO2024173699A2 (en) * 2023-02-16 2024-08-22 Mammoth Biosciences, Inc. Compositions for the treatment of spinal muscular atrophy
WO2024186892A2 (en) * 2023-03-06 2024-09-12 The Children's Hospital Of Philadelphia Regulated control of rna interference by alternative splicing
EP4701634A1 (en) 2023-04-28 2026-03-04 Kriya Therapeutics, Inc. Riboswitches for regulating gene expression and therapeutic methods of using the same
AU2024286618A1 (en) 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
WO2026125303A1 (en) 2024-12-11 2026-06-18 F. Hoffmann-La Roche Ag Inducible gene expression system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838657B2 (en) * 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
GB2443186A (en) * 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
US8633019B2 (en) * 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
HUE047898T2 (hu) * 2013-10-28 2020-05-28 Invectys Telomerázt kódoló DNS vakcina
CN108603230A (zh) * 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
JP2019535789A (ja) * 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
US20210355509A1 (en) * 2018-08-07 2021-11-18 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
CN114174514A (zh) * 2019-07-25 2022-03-11 诺华股份有限公司 可调节的表达系统
WO2022204471A1 (en) * 2021-03-26 2022-09-29 Ptc Therapeutics Inc. Regulation of transgene expression using a small molecule inducible splicing switch
CN118480543A (zh) * 2024-03-01 2024-08-13 五邑大学 一种可变剪接调节元件及其应用

Also Published As

Publication number Publication date
WO2021163556A1 (en) 2021-08-19
CN115605596A (zh) 2023-01-13
JP7728772B2 (ja) 2025-08-25
JP2023514242A (ja) 2023-04-05
US20230340498A1 (en) 2023-10-26
EP4103717A4 (en) 2024-02-28
CA3167836A1 (en) 2021-08-19
EP4103717A1 (en) 2022-12-21
KR20220146501A (ko) 2022-11-01
AU2021218807A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
JP7728772B2 (ja) 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法
JP7615021B2 (ja) 遺伝子発現の選択的スプライシング調節および治療方法
IL293140A (en) Vector variants of adenoviruses
JP2022050575A (ja) 家族性高コレステロール血症を処置するための遺伝子治療
US12383615B2 (en) Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
TW202444910A (zh) 編碼casx之信使rna
CN115667530A (zh) 非病毒dna载体和其用于表达因子ix治疗剂的用途
Gapinske et al. Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
WO2024186892A2 (en) Regulated control of rna interference by alternative splicing
US20250303000A1 (en) Compositions and methods for inducible alternative splicing regulation of gene expression
US20250207111A1 (en) Mobile genetic elements from eptesicus fuscus
US20240307557A1 (en) Therapeutic gene silencing with crispr-cas13
HK40048158A (en) Alternative splicing regulation of gene expression and therapeutic methods
RU2845941C1 (ru) Варианты аденоассоциированного вирусного вектора
US12312584B2 (en) cGMP exosome loaded therapeutics for treating sickle cell disease
Chai Precision Gene Editing for Muscle Diseases
TW202604549A (zh) 基因治療劑之剖析
WO2026064736A1 (en) Parvovirus compositions and related methods for gene therapy
WO2026064739A1 (en) Parvovirus compositions and related methods for gene therapy
WO2025186726A1 (en) Modulating expression of agt (angiotensinogen) gene
WO2025231406A1 (en) Methods to increase transduction of ependyma cells in brain